search
Back to results

The Effect of a Ketone Drink on Liver Glucose Production in People With Type 2 Diabetes (KES2)

Primary Purpose

Diabetes Mellitus, Ketosis

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Ketone - beta-hydroxybutyrate (β-OHB)
Sponsored by
University of Exeter
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Diabetes Mellitus focused on measuring Diabetes, Exogenous ketones, Postprandial glycemia, Endogenous glucose production

Eligibility Criteria

18 Years - 69 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosed with type 2 diabetes by a physician, a current HbA1c of 6.5-8.5%, and receiving treatment with lifestyle advice or oral glucose-lowering medications.
  • Non-smoking
  • Blood pressure <160/100 mm/Hg

Exclusion Criteria:

  • Exogenous insulin or SGLT2 inhibitors for type 2 diabetes treatment.
  • Following a low-carbohydrate ketogenic diet, periodic fasting diet, or consuming ketogenic supplements.
  • Other diagnosed chronic metabolic, cardiovascular, respiratory, neurological, or gastrointestinal disease.
  • Smoker
  • Blood pressure >160/100 mm/Hg
  • Lactose intolerant

Sites / Locations

  • Sport & Health Sciences, University of ExeterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Ketone

Placebo

Arm Description

Ketone monester (beta-hydroxybutyrate (β-OHB)

Non-caloric placebo

Outcomes

Primary Outcome Measures

EGP
Endogenous glucose production

Secondary Outcome Measures

Postprandial glycemia
Postprandial glucose concentrations
Insulin
Serum insulin concentration
Plasma β-OHB
Plasma β-OHB concentrations

Full Information

First Posted
August 24, 2022
Last Updated
August 24, 2022
Sponsor
University of Exeter
Collaborators
University of British Columbia
search

1. Study Identification

Unique Protocol Identification Number
NCT05518448
Brief Title
The Effect of a Ketone Drink on Liver Glucose Production in People With Type 2 Diabetes
Acronym
KES2
Official Title
The Effect of a Ketone Drink on Liver Glucose Production in People With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 3, 2022 (Actual)
Primary Completion Date
January 1, 2023 (Anticipated)
Study Completion Date
January 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Exeter
Collaborators
University of British Columbia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
What is the effect of a ketone drink on liver glucose production, and postprandial glycemia, in people with type 2 diabetes.
Detailed Description
Background: Ketones are molecules that are naturally produced by our body during fasting or diets low in carbohydrates. Ketones can affect how our liver produces and maintains our body's blood sugar levels, which could be important in the management of type 2 diabetes (T2D), where high blood sugar levels are partly because of excess sugar production by the liver. Objectives: To determine if, and how, a ketone drink can lower blood glucose in people with T2D following a meal. Methods: Twelve people with T2D will visit our laboratory in the morning on two occasions and ingest a drink containing ketones or placebo on each visit in a random order before ingesting a milkshake style drink containing sugar. Blood samples will then be taken at regular intervals over 4 hours to determine if the ketone drink has lowered blood sugar levels in response to the meal, and if this was due to reduced sugar production by the liver. Value: This research will provide new knowledge about the regulation of liver blood sugar production in response to ketone ingestion. This may also inform future clinical trials to establish if ketone drinks could be used as a treatment for T2D.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Ketosis
Keywords
Diabetes, Exogenous ketones, Postprandial glycemia, Endogenous glucose production

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Ketone vs placebo crossover
Masking
ParticipantInvestigator
Masking Description
Double-blind
Allocation
Randomized
Enrollment
12 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Ketone
Arm Type
Experimental
Arm Description
Ketone monester (beta-hydroxybutyrate (β-OHB)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Non-caloric placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
Ketone - beta-hydroxybutyrate (β-OHB)
Intervention Description
Ketone - beta-hydroxybutyrate (β-OHB)
Primary Outcome Measure Information:
Title
EGP
Description
Endogenous glucose production
Time Frame
6 hours
Secondary Outcome Measure Information:
Title
Postprandial glycemia
Description
Postprandial glucose concentrations
Time Frame
4 hours
Title
Insulin
Description
Serum insulin concentration
Time Frame
6 hours
Title
Plasma β-OHB
Description
Plasma β-OHB concentrations
Time Frame
6 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosed with type 2 diabetes by a physician, a current HbA1c of 6.5-8.5%, and receiving treatment with lifestyle advice or oral glucose-lowering medications. Non-smoking Blood pressure <160/100 mm/Hg Exclusion Criteria: Exogenous insulin or SGLT2 inhibitors for type 2 diabetes treatment. Following a low-carbohydrate ketogenic diet, periodic fasting diet, or consuming ketogenic supplements. Other diagnosed chronic metabolic, cardiovascular, respiratory, neurological, or gastrointestinal disease. Smoker Blood pressure >160/100 mm/Hg Lactose intolerant
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Francis Stephens, Phd
Phone
+44 (0)1392 72 2157
Email
F.B.Stephens@exeter.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Alistair Monteyne, Phd
Email
a.monteyne2@exeter.ac.uk
Facility Information:
Facility Name
Sport & Health Sciences, University of Exeter
City
Exeter
State/Province
Devon
ZIP/Postal Code
EX1 2LU
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francis Stephens, PhD
Phone
+44 (0)1392 72 2157
Email
F.B.Stephens@exeter.ac.uk

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Effect of a Ketone Drink on Liver Glucose Production in People With Type 2 Diabetes

We'll reach out to this number within 24 hrs